Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT04605952 Completed - Covid19 Clinical Trials

Study to Find the Percentage of Cases Retaining COVID-19 IgG Antibodies 45-65 After They Have Tested Positive

Start date: July 1, 2020
Phase:
Study type: Observational

As a serosurveillance measure asymptomatic employees of an industrial workforce Jamshedpur (India) were tested for COVID-19 IgG antibodies. Of the tested employees who were positive for COVID-19 IgG antibodies the study aimed to find the percentage of cases who retained their COVID-19 IgG antibodies 45-65 days after initially testing positive.

NCT ID: NCT04605692 Completed - COVID-19 Clinical Trials

Evaluation of Occupational Burnout and Stress Among Dentists in Covid-19 Pandemic

MBI
Start date: March 9, 2020
Phase:
Study type: Observational

The aim of this study was to evaluate the factors affecting the ability and willingness of dentists to work during the COVID-19 pandemic and the effect of this situation on occupational burnout. A 51-question survey, including demographic and pandemic questions and the Maslach Burnout Inventory (MBI), was used as a data collection method and administered to dentists in Turkey via the internet in two stages. A link to the survey (onlineanketler.com) was sent to the participants by e-mail or social media (WhatsApp©). A total of 706 participants were included in the study. The second stage of the survey only applied to dentists who are assigned within the scope of COVID-19 measures in Turkey.

NCT ID: NCT04604704 Completed - Covid19 Clinical Trials

Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome

Start date: January 28, 2021
Phase: Phase 2
Study type: Interventional

Pilot study into low dose naltrexone (LDN) and NAD+ for treatment of patients with post-COVID-19 syndrome.

NCT ID: NCT04603924 Completed - COVID-19 Clinical Trials

Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

Start date: October 7, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

Study of ANA001 in Moderate and Severe COVID-19 Patients

NCT ID: NCT04603729 Completed - Covid 19 Disease Clinical Trials

Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease

covid19
Start date: May 30, 2020
Phase: Phase 3
Study type: Interventional

The investigator will select participants with moderate to severe covid 19 disease admitted in Fatima memorial hospital. The investigator will divide them in two groups according to convenience sampling. Group 1 will be given dexamethasone 8mg/day and group 2 will be given methylprednisolone 1mg/kg/day IV for 5 days. The investigator will compare the improvement in temperature, oxygen requirement and CRP level at day zero and day 5 in both the groups.

NCT ID: NCT04603690 Completed - Covid-19 Clinical Trials

Oral Curcumin, Quercetin and Vitamin D3 Supplements for Mild to Moderate Symptoms of COVID-19

Start date: August 16, 2021
Phase: N/A
Study type: Interventional

The present study is aimed to investigate the treatment benefits of a combination of dietary supplements quercetin, curcumin and vitamin D3 as add-on therapy to the routine care for early mild symptoms of COVID-19 infection in outpatients setting.

NCT ID: NCT04603677 Completed - Covid19 Clinical Trials

Northern Colorado COVID-19 Biobank

NoCo-CoBio
Start date: July 8, 2020
Phase:
Study type: Observational

The NoCo-CoBio Project is a biobanking effort to store and preserve saliva, nasopharyngeal, stool and blood specimens from SARS-CoV-2 PCR (polymerase chain reaction) positive individuals.

NCT ID: NCT04603664 Completed - Clinical trials for Biochemical Markers ,NGAL,Cystatin c, Acute Kidneyinjury, Covid 19

Role of NGAL and Cystatin C in Prediction of Acute Kidney Injury Covid-19 Infection

Start date: October 30, 2020
Phase:
Study type: Observational

Recent different biomarkers of acute kidney injury (AKI) have been manufactured by pharmaceutical industry. Studies proved that Neutrophil gelatinase-associated lipocalin (NGAL) and cystatin c are effective predictive biomarkers for early acute kidney injury in septic patients and in children after cardiopulmonary bypass. This study hypothesize that both cystatin c and Neutrophil gelatinase-associated lipocalin can predict AKI in patients with COVID-19 before elevation of serum urea and creatinine which may help early interference.

NCT ID: NCT04602949 Completed - Covid19 Clinical Trials

Detection of COVID-19 Using Breath Analysis - Validation Study

COVID-19
Start date: November 12, 2020
Phase: N/A
Study type: Interventional

DETECTION OF THE 2019 NOVEL CORONAVIRUS (SARS-CoV-2) USING BREATH ANALYSIS- VALIDATION STUDY

NCT ID: NCT04602884 Completed - Covid19 Clinical Trials

Early Detection of COVID-19 Using Breath Analysis

COVID-19
Start date: September 22, 2020
Phase: N/A
Study type: Interventional

EARLY DETECTION OF COVID-19 USING BREATH ANALYSIS- FIRST CROSS-SECTIONAL STUDY